Role of neuropeptides in migraine: Where do they stand in the latest expert recommendations in migraine treatment?
Abbreviated Journal Title
Drug Dev. Res.
headache; trigeminovascular system; substance P; calcitonin gene-related; peptide; GENE-RELATED PEPTIDE; CAUDAL TRIGEMINAL NUCLEUS; RECEPTOR ANTAGONIST; BIBN4096BS; FAMILIAL HEMIPLEGIC MIGRAINE; FOS-LIKE IMMUNOREACTIVITY; VASOACTIVE INTESTINAL POLYPEPTIDE; NEUROGENIC PLASMA EXTRAVASATION; ENKEPHALIN-LIKE MATERIAL; NOCICEPTIVE DURAL INPUT; SUPERIOR SAGITTAL; SINUS; Chemistry, Medicinal; Pharmacology & Pharmacy
Many factors have been implicated in the pathogenesis of migraine headache, including activation of the trigeminovascular system, dysfunction of: cerebral blood vessels, circulating vasoactive substances, mitochondrial energy metabolism, brain oxygenation and metabolism, platelet disorder, alterations in serotonin levels, low levels of brain tissue magnesium, altered transport of ions across the cell membrane, and inheritance and dysfunction of the brainstem periaqueductal gray matter. The headache phase of migraine is associated with cerebral vasodilation and inflammation, presumably mediated by the release of vasoactive substances and neuropeptides including CGRP (calcitonin gene-related peptide). Increased serum CGRP levels have been detected during migraine and cluster headache. One strategy to treat migraine is to inhibit the release of neuropeptides or to block their receptors. This article briefly reviews some experimental and clinical investigations focused on neuropeptide involvement in migraine.
Drug Development Research
"Role of neuropeptides in migraine: Where do they stand in the latest expert recommendations in migraine treatment?" (2007). Faculty Bibliography 2000s. 7608.